 |
5 Products |  |
29 Diseases | | 5 Products |
|
3 Trials |  |
370 News |  |
| 12345» |
- | Keytruda (pembrolizumab) / Merck (MSD), vidutolimod (CMP-001) / Regeneron
Trial primary completion date: CMP-001 for Relapsed and Refractory Lymphoma (clinicaltrials.gov) - Nov 21, 2024
P1/2, N=39, Active, not recruiting, Sponsor: Umar Farooq
Trial primary completion date: Apr 2025 --> Aug 2024
- || Opdivo (nivolumab) / BMS, vidutolimod (CMP-001) / Regeneron
P2 data, Journal, PD(L)-1 Biomarker, IO biomarker: Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial. (Pubmed Central) - Nov 13, 2024
P2
Our findings support that combined vidutolimod and nivolumab stimulates a broad anti-tumor immune response and is associated with distinct baseline myeloid gene signature and gut microbiota. ClinicalTrials.gov identifier: NCT03618641.
- | vidutolimod (CMP-001) / Regeneron
Journal, Combination therapy, PD(L)-1 Biomarker, IO biomarker, Metastases: Intratumoral vidutolimod in combination with PD-1 blockade in locoregionally advanced melanoma. (Pubmed Central) - Nov 13, 2024
In this issue of Cancer Cell, Davar and colleagues report a promising phase 2 neoadjuvant trial of the TLR9 agonist vidutolimod in combination with nivolumab. Analyses suggest a unique myeloid expression signature is associated with response.
- | Keytruda (pembrolizumab) / Merck (MSD), vidutolimod (CMP-001) / Regeneron
Enrollment closed: CMP-001 for Relapsed and Refractory Lymphoma (clinicaltrials.gov) - Nov 12, 2024
P1/2, N=39, Active, not recruiting, Sponsor: Umar Farooq
Analyses suggest a unique myeloid expression signature is associated with response. Suspended --> Active, not recruiting
- ||||| Libtayo (cemiplimab-rwlc) / Regeneron, vidutolimod (CMP-001) / Regeneron
Trial termination, Combination therapy, Metastases: A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer (clinicaltrials.gov) - Nov 8, 2024
P2, N=77, Terminated, Sponsor: Regeneron Pharmaceuticals
Suspended --> Active, not recruiting Active, not recruiting --> Terminated; Sponsor Decision related to study drug supply
- | Keytruda (pembrolizumab) / Merck (MSD), vidutolimod (CMP-001) / Regeneron
Biomarker, Trial completion date, Trial primary completion date: A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma (clinicaltrials.gov) - Nov 4, 2024
P2, N=60, Suspended, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Terminated; Sponsor Decision related to study drug supply Trial completion date: Dec 2024 --> Jun 2025 | Trial primary completion date: Dec 2024 --> Jun 2025
- ||| vidutolimod (CMP-001) / Regeneron
Trial termination: CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma (clinicaltrials.gov) - Oct 23, 2024
P2, N=44, Terminated, Sponsor: Regeneron Pharmaceuticals
Trial completion date: Dec 2024 --> Jun 2025 | Trial primary completion date: Dec 2024 --> Jun 2025 Completed --> Terminated; Business Decision
- ||| vidutolimod (CMP-001) / Regeneron
Trial termination, Monotherapy: CMP-001-011: CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma (clinicaltrials.gov) - Oct 23, 2024
P2/3, N=20, Terminated, Sponsor: Regeneron Pharmaceuticals
Completed --> Terminated; Business Decision Completed --> Terminated; Business Decision
- ||| vidutolimod (CMP-001) / Regeneron
Trial termination, Metastases: CMP-001-007: CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Oct 23, 2024
P2, N=24, Terminated, Sponsor: Regeneron Pharmaceuticals
Completed --> Terminated; Business Decision Completed --> Terminated; Business Decision
- Opdivo (nivolumab) / BMS, vidutolimod (CMP-001) / Regeneron
Biomarker, Trial completion, Trial completion date, Trial primary completion date: Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination with Nivolumab Vs. Nivolumab (clinicaltrials.gov) - Oct 21, 2024
P2, N=9, Completed, Sponsor: Diwakar Davar
Completed --> Terminated; Business Decision Active, not recruiting --> Completed | Trial completion date: Jul 2028 --> Aug 2024 | Trial primary completion date: Jul 2028 --> Aug 2024
- vidutolimod (CMP-001) / Regeneron
Intratumoral injection of vidutolimod, an immunostimulatory virus-like particle, enhances the number of intratumoral and circulating tumor-specific CD8 T cells (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_917;
Conclusions Vidutolimod induced a greater influx of OT-1 T cells into the primary tumor and in circulation which supports previous studies that saw an abscopal effect of non-treated tumors. Vidutolimod also increased the number of circulation PD-1+ OT-1 T cells which supports clinical research of anti-PD-1 therapy in combination with vidutolimod Ethics Approval Mouse studies were approved by and performed according to guidelines established by the University of Iowa Institutional Animal Care and Use Committee under an approved IACUC Protocol #3011236.
- || vidutolimod (CMP-001) / Regeneron
Trial completion, Monotherapy: CMP-001-011: CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma (clinicaltrials.gov) - Aug 14, 2024
P2/3, N=20, Completed, Sponsor: Regeneron Pharmaceuticals
Vidutolimod also increased the number of circulation PD-1+ OT-1 T cells which supports clinical research of anti-PD-1 therapy in combination with vidutolimod Ethics Approval Mouse studies were approved by and performed according to guidelines established by the University of Iowa Institutional Animal Care and Use Committee under an approved IACUC Protocol #3011236. Active, not recruiting --> Completed
- ||| Libtayo (cemiplimab-rwlc) / Regeneron, vidutolimod (CMP-001) / Regeneron
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer (clinicaltrials.gov) - Aug 13, 2024
P2, N=77, Active, not recruiting, Sponsor: Regeneron Pharmaceuticals
Active, not recruiting --> Completed Suspended --> Active, not recruiting | N=225 --> 77 | Trial completion date: Jul 2027 --> Oct 2024 | Trial primary completion date: Jul 2027 --> Oct 2024
- | Opdivo (nivolumab) / BMS, vidutolimod (CMP-001) / Regeneron
Trial suspension: Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Aug 9, 2024
P2, N=10, Suspended, Sponsor: Emory University
Suspended --> Active, not recruiting | N=225 --> 77 | Trial completion date: Jul 2027 --> Oct 2024 | Trial primary completion date: Jul 2027 --> Oct 2024 Recruiting --> Suspended
- ivuxolimab (PF-04518600) / Pfizer, PD 360324 / Pfizer, utomilumab (PF-05082566) / Pfizer
Phase classification, Combination therapy, Metastases: A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) (clinicaltrials.gov) - Jul 29, 2024
P1/2, N=409, Terminated, Sponsor: Pfizer
Recruiting --> Suspended Phase classification: P1b/2 --> P1/2
- ||| Opdivo (nivolumab) / BMS, vidutolimod (CMP-001) / Regeneron
Biomarker, Enrollment closed, Enrollment change, Trial completion date: Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination with Nivolumab Vs. Nivolumab (clinicaltrials.gov) - May 3, 2024
P2, N=9, Active, not recruiting, Sponsor: Diwakar Davar
Phase classification: P1b/2 --> P1/2 Suspended --> Active, not recruiting | N=36 --> 9 | Trial completion date: Jul 2030 --> Jul 2028
- PRE-ISPY phase I/Ib oncology platform program (PRE-I-SPY-P1). () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5186;
P1
2 or other phase 2/3 trials. The first patient was enrolled on 2/1/2023.
- |||||| Libtayo (cemiplimab-rwlc) / Regeneron, vidutolimod (CMP-001) / Regeneron
Trial suspension, Combination therapy, Metastases: A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer (clinicaltrials.gov) - Apr 4, 2024
P2, N=225, Suspended, Sponsor: Regeneron Pharmaceuticals
The first patient was enrolled on 2/1/2023. Recruiting --> Suspended
- ||||| Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing (clinicaltrials.gov) - Apr 4, 2024
P3, N=61, Active, not recruiting, Sponsor: Pfizer
Recruiting --> Suspended Recruiting --> Active, not recruiting | N=262 --> 61 | Trial completion date: May 2025 --> Sep 2026 | Trial primary completion date: May 2025 --> Sep 2026
- ||| Keytruda (pembrolizumab) / Merck (MSD), vidutolimod (CMP-001) / Regeneron
Trial suspension: CMP-001 for Relapsed and Refractory Lymphoma (clinicaltrials.gov) - Mar 26, 2024
P1/2, N=39, Suspended, Sponsor: Umar Farooq
Recruiting --> Active, not recruiting | N=262 --> 61 | Trial completion date: May 2025 --> Sep 2026 | Trial primary completion date: May 2025 --> Sep 2026 Recruiting --> Suspended
- | Keytruda (pembrolizumab) / Merck (MSD), vidutolimod (CMP-001) / Regeneron
Biomarker, Trial suspension: A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma (clinicaltrials.gov) - Mar 21, 2024
P2, N=60, Suspended, Sponsor: National Cancer Institute (NCI)
Recruiting --> Suspended Recruiting --> Suspended
- || vidutolimod (CMP-001) / Regeneron
Trial completion: CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma (clinicaltrials.gov) - Feb 25, 2024
P2, N=44, Completed, Sponsor: Regeneron Pharmaceuticals
Recruiting --> Suspended Active, not recruiting --> Completed
- ||| Opdivo (nivolumab) / BMS, vidutolimod (CMP-001) / Regeneron
Biomarker, Trial suspension: Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination with Nivolumab Vs. Nivolumab (clinicaltrials.gov) - Feb 15, 2024
P2, N=36, Suspended, Sponsor: Diwakar Davar
Active, not recruiting --> Completed Recruiting --> Suspended
- |||| Trial completion date, Trial primary completion date: Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing (clinicaltrials.gov) - Feb 15, 2024
P3, N=262, Recruiting, Sponsor: Pfizer
Recruiting --> Suspended Trial completion date: Dec 2025 --> May 2025 | Trial primary completion date: Dec 2025 --> May 2025
- || Libtayo (cemiplimab-rwlc) / Regeneron, vidutolimod (CMP-001) / Regeneron
Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer (clinicaltrials.gov) - Feb 15, 2024
P2, N=225, Recruiting, Sponsor: Regeneron Pharmaceuticals
Trial completion date: Dec 2025 --> May 2025 | Trial primary completion date: Dec 2025 --> May 2025 Trial completion date: Mar 2027 --> Jul 2027 | Trial primary completion date: Mar 2027 --> Jul 2027
- | vidutolimod (CMP-001) / Regeneron
Trial completion date, Trial primary completion date: CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma (clinicaltrials.gov) - Feb 15, 2024
P2, N=44, Active, not recruiting, Sponsor: Regeneron Pharmaceuticals
Trial completion date: Mar 2027 --> Jul 2027 | Trial primary completion date: Mar 2027 --> Jul 2027 Trial completion date: Oct 2024 --> Feb 2024 | Trial primary completion date: Oct 2024 --> Feb 2024
- || vidutolimod (CMP-001) / Regeneron
Trial completion, Metastases: CMP-001-007: CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Feb 2, 2024
P2, N=24, Completed, Sponsor: Regeneron Pharmaceuticals
Trial completion date: Oct 2024 --> Feb 2024 | Trial primary completion date: Oct 2024 --> Feb 2024 Active, not recruiting --> Completed
- | Opdivo (nivolumab) / Ono Pharma, BMS, vidutolimod (CMP-001) / Regeneron, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker, Surgery: Combination Treatment of Intratumoral Vidutolimod, Radiosurgery, Nivolumab, and Ipilimumab for Microsatellite Stable Colorectal Carcinoma With Liver Metastases. (Pubmed Central) - Dec 4, 2023
The combination of intratumoral vidutolimod, radiosurgery, nivolumab and ipilimumab was not found to be efficacious in MSS mCRC with liver metastases. The juxtaposition of liver irradiation and intratumoral vidutolimod injection was associated with high hepatic toxicity.
- | vidutolimod (CMP-001) / Regeneron
Trial completion date, Trial primary completion date, Metastases: CMP-001-007: CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Nov 18, 2023
P2, N=24, Active, not recruiting, Sponsor: Regeneron Pharmaceuticals
The juxtaposition of liver irradiation and intratumoral vidutolimod injection was associated with high hepatic toxicity. Trial completion date: Jul 2024 --> Jan 2024 | Trial primary completion date: Jul 2024 --> Jan 2024
- |||||| vidutolimod (CMP-001) / Regeneron
New trial: Compassionate Use of Vidutolimod (clinicaltrials.gov) - Oct 3, 2023
P=N/A, N=0, Available, Sponsor: Regeneron Pharmaceuticals
- vidutolimod (CMP-001) / Regeneron
Vidutolimod, an immunostimulatory virus-like particle, reduces proliferation but enhances the activation of tumor-specific T cells (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_1425;
Conclusions Vidu reduces proliferation but enhances phenotypic markers of activation expressed by tumor-specific CD8+ T cells (OT-1 cells) when co-cultured with cells expressing OVA, their target antigen. Markers of activation are most notable in dividing OT-1 CD8+ T cells.
- | Opdivo (nivolumab) / BMS, vidutolimod (CMP-001) / Regeneron
Enrollment open: Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Aug 7, 2023
P2, N=10, Recruiting, Sponsor: Emory University
Markers of activation are most notable in dividing OT-1 CD8+ T cells. Not yet recruiting --> Recruiting
- ||||| Keytruda (pembrolizumab) / Merck (MSD), vidutolimod (CMP-001) / Regeneron
Clinical, Combination therapy: EA6194, led by @ATarhiniMDPhD of @MoffittNews and Diwakar Davar, MD of @UPMCHillmanCC, is studying the effect of pembrolizumab alone or in combination with CMP-001 in treating patients with operable #melanoma. For more: https://t.co/o5G3h83xC1 #melsm (Twitter) - Aug 3, 2023
- ||||| Keytruda (pembrolizumab) / Merck (MSD), vidutolimod (CMP-001) / Regeneron
Clinical, Combination therapy: EA6194, led by @ATarhiniMDPhD of @MoffittNews and Diwakar Davar, MD of @UPMCHillmanCC, is studying the effect of pembrolizumab alone or in combination with CMP-001 in treating patients with operable #melanoma. For more: https://t.co/o5G3h83xC1 #melsm (Twitter) - Jul 25, 2023
- ||||| Keytruda (pembrolizumab) / Merck (MSD), vidutolimod (CMP-001) / Regeneron
Clinical, Combination therapy: EA6194, led by @ATarhiniMDPhD of @MoffittNews and Diwakar Davar, MD of @UPMCHillmanCC, is studying the effect of pembrolizumab alone or in combination with CMP-001 in treating patients with operable #melanoma. For more: https://t.co/o5G3h83xC1 #melsm (Twitter) - Jun 1, 2023
- ||||| Keytruda (pembrolizumab) / Merck (MSD), vidutolimod (CMP-001) / Regeneron
Clinical, Combination therapy: EA6194, led by @ATarhiniMDPhD of @MoffittNews and Diwakar Davar, MD of @UPMCHillmanCC, is studying the effect of pembrolizumab alone or in combination with CMP-001 in treating patients with operable #melanoma. For more: https://t.co/o5G3h83xC1 #melsm (Twitter) - May 11, 2023
- |||||| ivuxolimab (PF-04518600) / Pfizer, PD 360324 / Pfizer, utomilumab (PF-05082566) / Pfizer
Trial termination, Combination therapy, IO biomarker, Metastases: A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) (clinicaltrials.gov) - May 8, 2023
P1b/2, N=405, Terminated, Sponsor: Pfizer
Active, not recruiting --> Terminated; The study was terminated since there was no need for further safety or efficacy data to be collected. The participants having benefit from the Investigational treatments have been moved to a continuation study (NCT05059522)
- | Opdivo (nivolumab) / BMS, vidutolimod (CMP-001) / Regeneron
Trial completion date: CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease (clinicaltrials.gov) - Apr 18, 2023
P2, N=34, Active, not recruiting, Sponsor: Diwakar Davar
The participants having benefit from the Investigational treatments have been moved to a continuation study (NCT05059522) Trial completion date: Mar 2023 --> Dec 2023
- || Opdivo (nivolumab) / BMS, vidutolimod (CMP-001) / Regeneron, Yervoy (ipilimumab) / BMS
Trial completion: CA209-991: Combined Immunotherapy and Radiosurgery for Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 18, 2023
P1, N=19, Completed, Sponsor: Sheba Medical Center
Trial completion date: Mar 2023 --> Dec 2023 Active, not recruiting --> Completed
- | Keytruda (pembrolizumab) / Merck (MSD), vidutolimod (CMP-001) / Regeneron
Trial completion date, Trial primary completion date: CMP-001 for Relapsed and Refractory Lymphoma (clinicaltrials.gov) - Apr 14, 2023
P1/2, N=39, Recruiting, Sponsor: Umar Farooq
Active, not recruiting --> Completed Trial completion date: Apr 2024 --> Apr 2026 | Trial primary completion date: Apr 2023 --> Apr 2025
- ||||| Keytruda (pembrolizumab) / Merck (MSD), vidutolimod (CMP-001) / Regeneron
Clinical, Combination therapy: EA6194, led by @ATarhiniMDPhD of @MoffittNews and Diwakar Davar, MD of @UPMCHillmanCC, is studying the effect of pembrolizumab alone or in combination with CMP-001 in treating patients with operable #melanoma. For more: https://t.co/o5G3h83xC1 #melsm (Twitter) - Apr 6, 2023
- || Libtayo (cemiplimab-rwlc) / Regeneron, vidutolimod (CMP-001) / Regeneron
Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer (clinicaltrials.gov) - Apr 4, 2023
P2, N=200, Recruiting, Sponsor: Regeneron Pharmaceuticals
Trial completion date: Apr 2024 --> Apr 2026 | Trial primary completion date: Apr 2023 --> Apr 2025 Trial completion date: Apr 2026 --> Mar 2027 | Trial primary completion date: Apr 2026 --> Mar 2027
- |||| Trial completion date, Trial primary completion date: Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing (clinicaltrials.gov) - Mar 27, 2023
P3, N=262, Recruiting, Sponsor: Pfizer
Trial completion date: Apr 2026 --> Mar 2027 | Trial primary completion date: Apr 2026 --> Mar 2027 Trial completion date: Nov 2024 --> Dec 2025 | Trial primary completion date: Nov 2024 --> Dec 2025
- | INCAGN1949 / Incyte, vidutolimod (CMP-001) / Regeneron
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Combination therapy, Metastases: CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma (clinicaltrials.gov) - Mar 22, 2023
P1/2, N=2, Terminated, Sponsor: University of Southern California
Trial completion date: Nov 2024 --> Dec 2025 | Trial primary completion date: Nov 2024 --> Dec 2025 N=42 --> 2 | Trial completion date: Apr 2024 --> Dec 2022 | Recruiting --> Terminated | Trial primary completion date: Apr 2023 --> Dec 2022; Study drug no longer available
- | Keytruda (pembrolizumab) / Merck (MSD), vidutolimod (CMP-001) / Regeneron
Biomarker, Trial completion date, Trial primary completion date: A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma (clinicaltrials.gov) - Mar 21, 2023
P2, N=54, Recruiting, Sponsor: National Cancer Institute (NCI)
N=42 --> 2 | Trial completion date: Apr 2024 --> Dec 2022 | Recruiting --> Terminated | Trial primary completion date: Apr 2023 --> Dec 2022; Study drug no longer available Trial completion date: Nov 2023 --> Dec 2024 | Trial primary completion date: Nov 2023 --> Dec 2024
- | vidutolimod (CMP-001) / Regeneron, Tecentriq (atezolizumab) / Roche
Journal, Combination therapy, Metastases: Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients (Pubmed Central) - Mar 17, 2023
P1b
In the two patients with initial tumor shrinkage in part A, a strong serum induction of C-X-C motif chemokine ligand 10 was observed. Vidutolimod and atezolizumab with and without RT had a manageable safety profile, with minimal clinical activity in heavily pretreated patients with programmed cell death protein 1 or programmed death-ligand 1 blockade-resistant NSCLC.
- Keytruda (pembrolizumab) / Merck (MSD), vidutolimod (CMP-001) / Regeneron
The XernaTM TME Panel potentially predicts response to a combination of the TLR9 agonist vidutolimod and PD-1 inhibitor pembrolizumab in metastatic melanomas with prior anti-PD-1 treatment (Section 40; Poster Board #11) - Mar 14, 2023 - Abstract #AACR2023AACR_4669;
P1b
Vidutolimod and atezolizumab with and without RT had a manageable safety profile, with minimal clinical activity in heavily pretreated patients with programmed cell death protein 1 or programmed death-ligand 1 blockade-resistant NSCLC. The Xerna TME Panel shows potential activity as a predictive and pharmacodynamic biomarker for the combination of vidutolimod and pembrolizumab in anti-PD-1 refractory melanoma patients.
- | Ampligen (rintatolimod) / AIM ImmunoTech, vidutolimod (CMP-001) / Regeneron
Journal: Trial watch: Toll-like receptor ligands in cancer therapy. (Pubmed Central) - Mar 7, 2023
Solid preclinical and translational results support the favorable immune-activating effects of TLR agonists. Here, we summarize recent preclinical and clinical advances in the development of TLR agonists for anticancer immunotherapy.
- | Opdivo (nivolumab) / BMS, vidutolimod (CMP-001) / Regeneron
Trial initiation date: Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Feb 8, 2023
P2, N=10, Not yet recruiting, Sponsor: Emory University
Here, we summarize recent preclinical and clinical advances in the development of TLR agonists for anticancer immunotherapy. Initiation date: Nov 2022 --> Jun 2023
- ||||| Keytruda (pembrolizumab) / Merck (MSD), vidutolimod (CMP-001) / Regeneron
Clinical, Combination therapy: EA6194, led by @ATarhiniMDPhD of @MoffittNews and Diwakar Davar, MD of @UPMCHillmanCC, is studying the effect of pembrolizumab alone or in combination with CMP-001 in treating patients with operable #melanoma. For more: https://t.co/o5G3h83xC1 #melsm (Twitter) - Feb 2, 2023